Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of in vivo-derived CMS4-met cells and the in vitro-derived CMS4.sel cells using CMS4 cells as a reference sample
The CMS4 sarcoma, kindly provided by A. DeLeo (University of Pittsburgh, Pittsburgh, PA), is a solid tumor of BALB/c (H-2d) origin, which grows aggressively in naive, syngeneic hosts following a s.c. transplant. Although the parental tumor cell line forms few metastatic foci in the lungs following i...
ORGANISM(S): Mus musculus 
2005-05-08 | E-MEXP-286 | biostudies-arrayexpress
ProteomicsProteomic Analysis of Outer Membrane Vesicles Derived from the Type A5 Strain of Mannheimia haemolytica
Mannheimia haemolytica (M. haemolytica) cause mastitis in sheep, acute sepsis in newborn lambs, and co-infections with various pathogens, leading to bovine respiratory disease syndrome (BRDS), these infections have resulted in significant economic losses to both domestic and international farming in...
ORGANISM(S): Mannheimia haemolytica M42548 
2025-06-30 | PXD064633 | Pride
Proteomics Outer membrane vesicles In vitro test. Inflammatory response Mannheimia haemolytica type a5 
UnknownLocating Interstitial Hydrides in MH2@Cu14 (M = Cu, Ag) Clusters by Single-Crystal X-ray Diffraction.
Not available
S-EPMC10468881 | biostudies-literature
MetabolomicsComparative metabolomic analysis of exudates of microcystin-producing and microcystin-free Microcystis aeruginosa strains

Cyanobacterial harmful algal blooms (cHABs) dominated by Microcystis aeruginosa threaten the ecological integrity and beneficial uses of lakes globally. In addition to producing hepatotoxic microcystins (MC), M. aeruginosa exudates (MaE) contain various compounds with demonstrat...

2023-01-16 | MTBLS6603 | MetaboLights
Metabolomics1H-NMR metabolomics identifies hypoxanthine as a novel metastasis-associated metabolite
Breast cancer is one of the leading causes of death in females, mainly because of metastasis. Oncometabolites, produced via metabolic reprogramming, can influence metastatic signaling cascades. Accordingly, and based on our previous results, we hypothesized that metabolites from highly metastatic br...
2025-09-19 | MTBLS7764 | MetaboLights
TranscriptomicsTranscriptional profiles of Campylobacter jejuni macrolide resistant strain JL272 to 4mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni 
2013-10-10 | E-GEOD-43025 | biostudies-arrayexpress
UnknownInteraction of uromodulin and complement factor H enhances C3b inactivation.
Not available
S-EPMC5020621 | biostudies-literature
TranscriptomicsTranscription profiling of mouse CMS4 and CMS4-met cell lines after IFNgamma treatment
The CMS4 sarcoma, kindly provided by A. DeLeo (University of Pittsburgh, Pittsburgh, PA), is a solid tumor of BALB/c (H-2d) origin, which grows aggressively in naive, syngeneic hosts following a s.c. transplant. Although the parental tumor cell line forms few metastatic foci in the lungs following i...
ORGANISM(S): Mus musculus 
2005-05-08 | E-MEXP-288 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni NCTC 11168 to 4mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 
2013-10-10 | E-GEOD-43023 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni NCTC 11168 to 0.125mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 
2013-10-10 | E-GEOD-43024 | biostudies-arrayexpress
Sort   by:  
 Page size